Showing results (1751-1760 of 19,551) with videos related to

Sort By:
Pageof 1,956
BMC Cancer|May 5, 2018
Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphomaJulian M M Rogasch, Patrick Hundsdoerfer, Frank Hofheinz, et al.
BMC Cancer|May 5, 2018
Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditionsMarkus Schulze, Maria Hutterer, Anja Sabo, et al.
BMC Cancer|May 6, 2018
Neuroendocrine carcinoma of the cervix: a systematic review of the literatureClemens B Tempfer, Iris Tischoff, Askin Dogan, et al.
BMC Cancer|May 6, 2018
PET/CT incidental detection of second tumor in patients investigated for pancreatic neoplasmsLucia Moletta, Sergio Bissoli, Alberto Fantin, et al.
BMC Cancer|July 26, 2018
Regulation of the oncogenic phenotype by the nuclear body protein ZC3H8John A Schmidt, Keith G Danielson, Emily R Duffner, et al.
BMC Cancer|July 26, 2018
Tailored exercise interventions to reduce fatigue in cancer survivors: study protocol of a randomized controlled trialRosie Twomey, Tristan Martin, John Temesi, et al.
BMC Cancer|July 27, 2018
S100A4 suppresses cancer stem cell proliferation via interaction with the IKK/NF-κB signaling pathwayYongtong Zhu, Yao Zhou, Xuan Zhou, et al.
BMC Cancer|July 30, 2018
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective studyIn Ae Kim, Jong Sik Lee, Hee Joung Kim, et al.
BMC Cancer|August 1, 2018
Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective studyMarie Viala, Akiko Chiba, Simon Thezenas, et al.
BMC Cancer|August 2, 2018
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, et al.
Pageof 1,956